STOCKS TELEGRAPH

Tag: ATHE

  • Alterity Therapeutics Limited (ATHE) stock is going up – What’s driving it higher?

    Alterity Therapeutics Limited (ATHE) has seen a push of 7.11% in premarket despite any latest news released by the company. However, the last trading session closed at $0.98 with an increase of 7.84%.

    ATH434 Being Neuroprotective – Latest News by ATHE

    On 28th January 2022, ATHE announced that the Journal of Parkinson’s Disease recently published evidence from an animal model of Multiple System Atrophy (MSA). MSA is a debilitating neurological disease for which there is no recognized treatment.

    The preclinical findings are extremely important because they support the hypothesis. The hypothesis stated that by binding and redistributing excess iron in the brains of Parkinson’s disease patients, they can decrease synuclein aggregation and oxidative stress, as well as rescue neurotransmitters in multiple brain regions. This addresses the disease’s underlying pathology. Last but not the least, ATHE anticipates that these preclinical studies will lead to clinical benefit in MSA patients.

    New US Patent – What’s up?

    On 6th January 2022, ATHE reported that the company has been granted a new patent number by the USPTO. The USPTO prioritized the investigation of the composition of matter patent, “Compounds for and Methods of Treating Diseases.” The patent includes more than 80 new compounds and grants exclusivity to a new class of iron chaperones meant to disperse excess iron.

    ATHE is still looking for new medication candidates to contribute to the portfolio and safeguard the neurodegenerative therapeutic approach. Moreover, ATHE is developing a strong basis as a leader in targeting iron for a possible disease-modifying therapy for critical neurological illnesses including Parkinson’s and Alzheimer’s.

    First Regulatory Authorization by ATHE – What’s going on?

    On 14th December 2021, ATHE announced that Alterity’s Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA), a rare and very debilitating Parkinsonian illness, has been approved by the New Zealand Medicines and Medical Devices Safety Authority. The approval of the New Zealand health authorities to proceed with the Phase 2 clinical research is an important milestone. This happens because it opens the door for the study to begin in the first quarter of next year. By preventing -synuclein aggregation and restoring iron balance in the brain, ATH434 uses a novel strategy to treat the underlying pathophysiology of MSA.

  • Alterity Therapeutics Ltd. (ATHE) stock Rallies After Hours. Any Reason?

    Alterity Therapeutics Ltd. (ATHE) stock gained a huge 35.05% in the after-hours on January 05. The stock seems to be gaining after the company announced its upcoming presentation at the H.C. Wainwright BIOCONNECT virtual conference.

    During regular trading, the stock fluctuated between $0.7900 and $0.8580 at 2.84 million shares. ATHE closed the session at $0.8293 with a gain of 3.65%. Following the announcement, the stock went up to $1.12 in the after-hours session on Wednesday.

    The neurodegenerative disease therapies developer, Alterity Therapeutics Ltd. has a market capitalization of $34.88 million. Currently, the company has 40.11 million shares outstanding in the market.

    ATHE’s Participations

    On Wednesday, the company announced that its CEO, David Stamler will be presenting at the H.C. Wainwright BIOCONNECT conference. The conference will be held virtually from January 10 to January 13, 2022.

    Previously, the company had also participated in two virtual investor conferences in November and December of 2021. Firstly, Mr. Stamler participated in the MST Financial Lifesciences & Biotech Forum. This conference was held on Thursday, November 25, 2021. Secondly, the CEO also participated in the Benckmark Company Discovery One-on-One Investor Conference. The one-on-one conference took place on Thursday, December 02 (U.S.) and Friday, December 03 (Australia).

    Regulatory Authorization for Phase 2 Trial of ATH434

    On December 14, the company announced receiving the first regulatory authorization for its Phase 2 clinical trial of ATH434. As per the news, the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) authorized the trial. Moreover, the Phase 2 clinical trial is designed for the evaluation of ATH434 in Multiple System Atrophy (MSA). MSA is a rare neurodegenerative disease that affects the autonomic nervous system and movement. Further, MSA is a Parkinsonian disorder with no drugs for slowing its progression and no cure.

    The Phase 2 trial is a double-blind, placebo-controlled, and randomized study of the efficacy, safety, and pharmacokinetics of ATH434. Furthermore, ATH434 is ATHE’s lead product candidate with the potential of treating Parkinson’s and its various forms. Previously, ATH434 demonstrated the successful completion of the Phase 1 clinical trial. Recently, the European Commission and the U.S. FDA granted Orphan designation to ATH434 for treating MSA.

    ATHE’s Q1 FY22 Quarterly Cash Flow

    According to Appendix 4C Quarterly Cash Flow Report for the Q1 FY22, ATHE had a cash balance of A$41.3 million. Furthermore, this cash position also includes proceeds of A$17.2 million from share issuance through the at-the-market facility in July 2021. In addition, the Q1 FY22 ended on September 30, 2021.

  • Alterity Therapeutics Ltd. (ATHE) Stock Surges as Scope of Patent is Explored in Treatment of Alzheimer’s and Parkinson’s

    Alterity Therapeutics Ltd. (ATHE) stock prices were down by 2.11%, bringing the price per share down to USD$1.39 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 30.22%, bringing it up to USD$1.81.

    USPTO Patent

    July 1st, 2021 saw the company announce that it had been granted a new composition of matter patent by the United States Patent and Trademark Office (USPTO). This patent will offer the company a vast monopoly over a new class of iron chaperons, which is a technology capable of redistributing excess iron in the central nervous system. The structural backbone presented in the patent serves as the foundation for small molecule drug candidates that have the capacity to cross the blood brain barrier, thus directly attacking sources of various neuropathologies.

    Scope of Patent

    Alzheimer’s and Parkinson’s are associated with excess levels of iron in the brain, as are various other important neurodegenerative diseases. Titled “Compounds for and Methods of Treating Diseases”, the patent was granted following an expedited review by the USPTO. It includes coverage of more than 150 novel pharmaceutical compositions that are designed to facilitate the redistribution of the labile iron that is involved in a myriad of neurodegenerative conditions.

    Dissecting the Patent

    The company is set to launch the Phase 2 trial of ATH434, its lead clinical candidate, by the end of the 2021 year. The small molecule drug is being developed for Multiple System Atrophy (MSA), which is a form of atypical parkinsonism where iron is essential in pathogenesis by promoting α-synuclein aggregation. Results from the Phase 2 study, in conjunction with the ongoing scientific investigation of the treatment, will facilitate the development and optimization of novel compounds that are expected to emerge from the new patent

    Continued Expansion

    The significant milestone represents an important part of our corporate strategy aimed to expand the company’s portfolio of potential disease modifying treatments for the demographic affected by neurodegenerative diseases. The newly covered compounds are designed to target excess brain iron resulting from the conditions, with the company hoping to identify a new clinical candidate by the time the lead clinical program results are reported.

    Future Outlook for ATHE

    Armed with the lucrative potential afforded by the granting of the patent, ATHE is poised to capitalize on the continued development of its lead product. The company is keen to continue its trajectory of success as it continues to explore added opportunities arising from the patent. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to usher in significant and sustained increases in shareholder value.

  • Alterity Therapeutics Ltd. (ATHE) Stock Skyrockets as Meme Stock Phenomenon Continues to Proliferate Stock Exchange

    Alterity Therapeutics Ltd. (ATHE) stock prices were down by 1.52% as of the market closing on June 30th 2021, bringing the price per share down to USD$1.30 at the end of the trading day. Subsequent pre-market fluctuations saw the stock skyrocket by a massive 66.92%, bringing it up to USD$2.17.

    EMA Guidance

    June 23rd, 2021 saw the company announce guidance it had received from the European Medicines Agency (EMA) in regard to key aspects of ATHE’s Phase 2 clinical trial for the treatment of Multiple System Atrophy (MSA) with its investigational drug ATH434. The company is actively preparing for the impending launch of the Phase 2 trial, which is scheduled to commence in the second half of 2021.

    About the EMA

    The EMA is an agency with jurisdiction in the European Union, with the responsibility of evaluating and supervising medicinal products. The agency plays a crucial role in the timely support of the sound development of high-quality, effective, and safe medicines for the treatment of respective patients. With their advice not being binding, the EMA influences improved trial designs to facilitate more robust and complete data in the evaluation of treatments.

    Scope of ATH434

    With MSA affecting a sizeable portion of the U.S population and the absence of any approved treatments for MSA, the scope of ATH434 is extensive. There is no regulatory precedence for defining clinical endpoints or guiding patient enrollment, thus requiring greater consideration in developing a trial design that is most suitable. Accordingly, the company has recruited clinical experts and global regulatory authorities for input. ATHE is also conducting BioMUSE, a natural history study designed to identify biomarkers and clinical endpoints most appropriate to capture efficacy signals in the Phase 2 study.

    Meme Stock Phenomenon

    Despite the promising development of the course of the ATH434 trial, the recent surge in ATHE’s stock price seems unmerited. Such drastic movement in the absence of news coverage or changes in fundamentals likely signals the company having been the latest target of the meme stock phenomenon that has resurged in the stock market. Driven by Reddit-based retail investors, underperforming companies with high short interest are selected for a coordinated short squeeze.

    Future Outlook for ATHE

    Armed with the recent surge in its equity value, ATHE finds itself with a fortuitous influx of resources to leverage in order to ensure more organic growth. Investors are hopeful that the company will manage to use the resources at its disposal to continue its trajectory of success.

  • Alterity Therapeutics Ltd. (ATHE) stock surged in the premarket trading session; here’s why

    In the premarket trading session, Alterity Therapeutics Limited (ATHE) has advanced by 3.85% to the price of $1.35 at the last check. ATHE stock had previously closed the session gaining 1.56% at $1.30. ATHE stock’s share price had traded between $1.26 and $1.30. ATHE stock traded 86997.0 shares. In the past week, ATHE’s shares have shed by -5.11%, while in the last month the shares added 1.56%.

    Atlerity Therapeutics’ focuses on the treatment of Parkinson disease

    Alterity Therapeutics is a biotechnology firm that specifically focuses on the discovering, designing and developing of treatments and therapy for the unmet needs of the health market. Alterity specifically focuses on developing a platform for the treatment of Parkinsonian’s disease as well as other neurodegenerative diseases. The company operates in Australia and is established in Melbourne. Founded in 1997, Alterity Therapeutics Limited was known previously as Prana Biotechnology Limited until April 2019. The main investigational candidate of the company includes ATH434 – a treatment for Parkinson’s disease- which has passed the Phase I clinical trial tests. Furthermore, Alterity is also producing antimicrobial agents such as PBT2.

    The third quarter Fiscal year 2021 report for ATHE stock shows expected growth and progress

    The company’s profile is in-line with the company’s own as well as analyst’s expectations and predictions of its financial performances. Furthermore, the company is also on track with the progress and preparation in clinical study operational phases.

    During the quarter, Alterity has made significant advances in the phase II trial of the lead candidate drug known as ATH434 which is being developed for Multiple System Atrophy (MSA) patients. The company mainly focused its efforts the conduction of bioMUSE Natural History study that is being done on MSA patients. The study will be conducted at Vanderbilt university medical center and provide insight on the design and blueprint of the phase II study of ATH434which is planned to start in this year later. The investigation has now enlisted 80% of the first objective populace and the organization is assessing the plausibility to grow enlistment.

    The organization’s money position was $32.8M with operational money surges of $5M, in accordance with organization assumptions and reflecting continuous groundwork for the Phase 2 clinical preliminary for Alterity’s lead drug up-and-comer ATH434 in Multiple System Atrophy (MSA) patients.

    The company is strengthening its profile at investments and by regularly participating in scientific and clinical conferences. The largest health conference hosted by JP Morgan also became the point for presenting the company, in the satellite event known as Biotech Showcase. January and March were both months in which the CEO of Alterity David Stamler presented poster presentations to introduce their lead candidate in HC Wainwright. Stamler was appointed the CEO of the company in January. Furthermore, the company was granted US$495,000 by Michael J. Fox Foundation to assess the pharmacologic profile of ATH434 to decide the ideal dosage of the medication in future Parkinson’s illness clinical preliminaries. It was the second award the organization has gotten from the Michael J. Fox Foundation for ATH434.

  • Stocks to Watch as Increasing COVID-19 Numbers Dampen Market Sentiment

    Stocks to Watch as Increasing COVID-19 Numbers Dampen Market Sentiment

    The markets are headed for a weak start this Tuesday. This follows news of a resurgence in COVID-19 numbers in the EU, the U. S and across the world. Already, Melbourne, Australia’s second-largest city is back in lockdown.  Another spike in COVID-19 cases could dampen hopes of a global economic reopening, and further, put a strain on the economy.

    The markets are also facing uncertainty due to the stalemate between democrats and republicans on the economic bailout. While Democrats have indicated that they are close to a deal with the Whitehouse, it is still uncertain of when such a deal will materialize due to a disagreement on the employment benefits extension. Despite this environment of a mixed outlook, there are stocks doing well pre-market mainly due to strong quarterly results. Some of the biggest performers ahead of markets opening are:

    Alterity Therapeutics Limited [NASDAQ:ATHE]

    Alterity Therapeutics Limited is one of the top performers pre-market and is up by over 200%. This comes after the company announced that it had got positive data for its MSA drug on animal testing. The company reported that data from Dr. Nadia Stefanova’s laboratory showed that ATH434 reduced a-synuclein pathology, and also led to improved motor performance.

    ATH434 is being developed as a treatment of Parkinson’s disease and MSA.  The research showed that the treatment was well-tolerated and showed effectiveness in a predictive animal model. Commenting on the research Alterity’s Chief Medical Officer, Dr. David Stamler stated that the animal testing data supports positive safety and pharmacokinetic clinical data that the company has released. This is a big deal and could see the stock rally all through the day.

    Danos Corporation [NYSE:DAC]

    Danos Corporation is another top performer pre-market and is up by 26%. This follows the company’s strong Q2 results.  The company reported an EPS of $1.71, slightly higher than the analyst consensus of $1.42. The company reported that its operating income increased to $116.8 million compared to $112.3 million in Q2 of 2019.

    The company stated that it was moving forward with its growth strategy and that it was cushioned from the market volatility. In its statement, the company also added that it was fully committed to technological innovation in a bid to satisfy its customers. As its strong quarterly results filter into the market, it could open the day in the green.

    Ossen Innovation Co Ltd [NASDAQ:OSN]

    Ossen Innovation Co is another top performer this morning and is up by 21% in pre-market trading.  There is no major news around this company at the moment, which makes it price action-driven. The stock has been gaining steadily, with volumes rising. This rally could be a breakout on a surge in volumes.